Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 433

1.

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients.

Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K.

Sci Rep. 2019 Jul 19;9(1):10529. doi: 10.1038/s41598-019-46609-7.

2.

Too many people with viral hepatitis are diagnosed late - with dire consequences.

Lazarus JV, Picchio C, Dillon JF, Rockstroh JK, Weis N, Buti M.

Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):451-452. doi: 10.1038/s41575-019-0177-z. No abstract available.

PMID:
31320742
3.

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.

Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M.

J Hepatol. 2019 Jun 14. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]

PMID:
31203153
4.

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M.

Liver Int. 2019 May 28. doi: 10.1111/liv.14155. [Epub ahead of print]

PMID:
31136052
5.

Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity.

Martínez-Valle F, Riveiro-Barciela M, Salcedo MT, Merino-Casabiel X, Fernández-Codina A, Torres I, Esteban R, Buti M.

Ann Hepatol. 2019 Jan - Feb;18(1):215-219. doi: 10.5604/01.3001.0012.7916.

6.

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators.

J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.

PMID:
31108015
7.

Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection.

Godoy C, Tabernero D, Sopena S, Gregori J, Cortese MF, González C, Casillas R, Yll M, Rando A, López-Martínez R, Quer J, González-Aseguinolaza G, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F.

World J Gastroenterol. 2019 Apr 7;25(13):1566-1579. doi: 10.3748/wjg.v25.i13.1566.

8.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
9.

Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.

Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9.

PMID:
30975477
10.

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

PMID:
30795958
11.

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level.

Karimzadeh H, Kiraithe MM, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C.

Gastroenterology. 2019 May;156(6):1820-1833. doi: 10.1053/j.gastro.2019.02.003. Epub 2019 Feb 12.

12.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.

Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team.

Hepatology. 2019 Jun;69(6):2349-2363. doi: 10.1002/hep.30527. Epub 2019 Mar 14.

PMID:
30693573
13.

Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.

Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):267-271. doi: 10.1097/MEG.0000000000001289.

PMID:
30576297
14.

Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?

Riveiro-Barciela M, Gironella M, Senín A, Salcedo MT, Merino-Casabiel X, Castells L, Esteban R, Buti M, Martínez-Valle F.

Hepatology. 2019 Jun;69(6):2701-2703. doi: 10.1002/hep.30464. Epub 2019 Mar 7. No abstract available.

PMID:
30561765
15.

Determination of Free Soluble Phenolic Compounds in Grains of Ancient Wheat Varieties ( Triticum sp. pl.) by Liquid Chromatography-Tandem Mass Spectrometry.

Montevecchi G, Setti L, Olmi L, Buti M, Laviano L, Antonelli A, Sgarbi E.

J Agric Food Chem. 2019 Jan 9;67(1):201-212. doi: 10.1021/acs.jafc.8b05629. Epub 2018 Dec 20.

PMID:
30525569
16.

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant.

Perales C, Chen Q, Soria ME, Gregori J, Garcia-Cehic D, Nieto-Aponte L, Castells L, Imaz A, Llorens-Revull M, Domingo E, Buti M, Esteban JI, Rodriguez-Frias F, Quer J.

Infect Drug Resist. 2018 Nov 8;11:2207-2210. doi: 10.2147/IDR.S172226. eCollection 2018.

17.

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

Riveiro-Barciela M, Muñoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-López R, Buti M.

J Hepatol. 2019 Mar;70(3):564-566. doi: 10.1016/j.jhep.2018.10.020. Epub 2018 Nov 28. No abstract available.

PMID:
30503040
18.

Healthcare value of implementing hepatitis C screening in the adult general population in Spain.

Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R.

PLoS One. 2018 Nov 28;13(11):e0208036. doi: 10.1371/journal.pone.0208036. eCollection 2018.

19.

HDV evolution-will viral resistance be an issue in HDV infection?

Tabernero D, Cortese MF, Buti M, Rodriguez-Frias F.

Curr Opin Virol. 2018 Oct;32:100-107. doi: 10.1016/j.coviro.2018.10.003. Epub 2018 Nov 8. Review.

PMID:
30415162
20.

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodríguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH.

Gastroenterology. 2019 Feb;156(3):635-646.e9. doi: 10.1053/j.gastro.2018.10.027. Epub 2018 Oct 17.

PMID:
30342034
21.

Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.

Dig Dis Sci. 2019 Jan;64(1):285-286. doi: 10.1007/s10620-018-5294-y.

PMID:
30324553
22.

Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin.

Riveiro-Barciela M, Bes M, Quer J, Valcarcel D, Piriz S, Gregori J, Llorens M, Salcedo MT, Piron M, Esteban R, Buti M, Sauleda S.

Transfusion. 2018 Nov;58(11):2501-2505. doi: 10.1111/trf.14831. Epub 2018 Oct 4.

PMID:
30284732
23.

Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH).

Calleja JL, Macias J, Forns X, Garcia F, Berenguer M, Garcia Deltoro M, Buti M, Granados R, Carrion JA, Morano L, Fernandez I, Coste P, Pineda JA.

Gastroenterol Hepatol. 2018 Nov;41(9):597-608. doi: 10.1016/j.gastrohep.2018.07.010. Epub 2018 Sep 27. English, Spanish. No abstract available.

PMID:
30270150
24.

Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.

Buchanan-Hughes AM, Buti M, Hanman K, Langford B, Wright M, Eddowes LA.

Qual Life Res. 2019 Feb;28(2):297-319. doi: 10.1007/s11136-018-1992-3. Epub 2018 Sep 17.

PMID:
30225787
25.

The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.

Roncero C, Villegas JL, Martínez-Rebollar M, Buti M.

Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030. doi: 10.1080/17512433.2018.1519392. Epub 2018 Sep 29. Review.

PMID:
30199279
26.

Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.

Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C.

BMC Infect Dis. 2018 Sep 3;18(1):446. doi: 10.1186/s12879-018-3356-6.

27.

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.

Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY.

Dig Dis Sci. 2018 Dec;63(12):3487-3497. doi: 10.1007/s10620-018-5251-9. Epub 2018 Aug 22. Erratum in: Dig Dis Sci. 2018 Oct 15;:.

28.

Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy.

Caballero A, Tabernero D, Buti M, Rodriguez-Frias F.

Antiviral Res. 2018 Oct;158:34-44. doi: 10.1016/j.antiviral.2018.07.019. Epub 2018 Jul 29. Review.

PMID:
30059722
29.

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.

Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01064-18. doi: 10.1128/AAC.01064-18. Print 2018 Oct.

30.

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M.

Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.

PMID:
29958855
31.

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Rubio MG, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R.

PLoS One. 2018 Jun 25;13(6):e0199926. doi: 10.1371/journal.pone.0199926. eCollection 2018.

32.

Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors' reply.

Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP.

Aliment Pharmacol Ther. 2018 Jul;48(2):235-236. doi: 10.1111/apt.14820. No abstract available.

PMID:
29939414
33.

Transcriptome profiling of short-term response to chilling stress in tolerant and sensitive Oryza sativa ssp. Japonica seedlings.

Buti M, Pasquariello M, Ronga D, Milc JA, Pecchioni N, Ho VT, Pucciariello C, Perata P, Francia E.

Funct Integr Genomics. 2018 Nov;18(6):627-644. doi: 10.1007/s10142-018-0615-y. Epub 2018 Jun 6.

PMID:
29876699
34.

Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy.

González C, Tabernero D, Cortese MF, Gregori J, Casillas R, Riveiro-Barciela M, Godoy C, Sopena S, Rando A, Yll M, Lopez-Martinez R, Quer J, Esteban R, Buti M, Rodríguez-Frías F.

World J Gastroenterol. 2018 May 21;24(19):2095-2107. doi: 10.3748/wjg.v24.i19.2095.

35.

Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction" [J Hepatol 67 (2017) 669-679].

Suárez-Amarán L, Usai C, Di Scala M, Godoy C, Ni Y, Hommel M, Palomo L, Segura V, Olagüe C, Vales A, Ruiz-Ripa A, Buti M, Salido E, Prieto J, Urban S, Rodríguez-Frias F, Aldabe R, González-Aseguinolaza G.

J Hepatol. 2018 Jul;69(1):262-264. doi: 10.1016/j.jhep.2018.04.003. No abstract available.

PMID:
29776712
36.

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators.

J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.

PMID:
29756595
37.

Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells.

Karimzadeh H, Kiraithe MM, Kosinska AD, Glaser M, Fiedler M, Oberhardt V, Salimi Alizei E, Hofmann M, Mok JY, Nguyen M, van Esch WJE, Budeus B, Grabowski J, Homs M, Olivero A, Keyvani H, Rodríguez-Frías F, Tabernero D, Buti M, Heinold A, Alavian SM, Bauer T, Schulze Zur Wiesch J, Raziorrouh B, Hoffmann D, Smedile A, Rizzetto M, Wedemeyer H, Timm J, Antes I, Neumann-Haefelin C, Protzer U, Roggendorf M.

J Virol. 2018 Jun 13;92(13). pii: e01891-17. doi: 10.1128/JVI.01891-17. Print 2018 Jul 1.

38.

Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation.

Lens S, García-Eliz M, Fernández I, Castells L, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X.

Liver Int. 2018 Nov;38(11):1940-1950. doi: 10.1111/liv.13858. Epub 2018 May 3.

PMID:
29660249
39.

The genome sequence and transcriptome of Potentilla micrantha and their comparison to Fragaria vesca (the woodland strawberry).

Buti M, Moretto M, Barghini E, Mascagni F, Natali L, Brilli M, Lomsadze A, Sonego P, Giongo L, Alonge M, Velasco R, Varotto C, Šurbanovski N, Borodovsky M, Ward JA, Engelen K, Cavallini A, Cestaro A, Sargent DJ.

Gigascience. 2018 Apr 1;7(4):1-14. doi: 10.1093/gigascience/giy010. Erratum in: Gigascience. 2018 Nov 1;7(11):.

40.

Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.

Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP.

Aliment Pharmacol Ther. 2018 May;47(9):1278-1287. doi: 10.1111/apt.14593. Epub 2018 Mar 7.

PMID:
29516535
41.

Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population.

Casillas R, Tabernero D, Gregori J, Belmonte I, Cortese MF, González C, Riveiro-Barciela M, López RM, Quer J, Esteban R, Buti M, Rodríguez-Frías F.

World J Gastroenterol. 2018 Feb 14;24(6):680-692. doi: 10.3748/wjg.v24.i6.680.

42.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P.

J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8.

PMID:
29427727
43.

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.

Buti M, Riveiro-Barciela M, Esteban R.

Liver Int. 2018 Feb;38 Suppl 1:84-89. doi: 10.1111/liv.13641. Review.

PMID:
29427500
44.

Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.

Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M.

J Hepatol. 2018 May;68(5):940-948. doi: 10.1016/j.jhep.2017.12.019. Epub 2017 Dec 28.

PMID:
29288753
45.

New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.

Ordeig L, Garcia-Cehic D, Gregori J, Soria ME, Nieto-Aponte L, Perales C, Llorens M, Chen Q, Riveiro-Barciela M, Buti M, Esteban R, Esteban JI, Rodriguez-Frias F, Quer J.

J Gen Virol. 2018 Jan;99(1):97-102. doi: 10.1099/jgv.0.000996. Epub 2017 Dec 14.

PMID:
29239718
46.

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.

Buti M, Riveiro-Barciela M, Esteban R.

J Infect Dis. 2017 Nov 16;216(suppl_8):S792-S796. doi: 10.1093/infdis/jix135.

PMID:
29156043
47.

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.

Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ.

Hepatology. 2018 Apr;67(4):1253-1260. doi: 10.1002/hep.29671. Epub 2018 Jan 30.

48.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
49.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA.

Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11.

50.

Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing.

Sopena S, Godoy C, Tabernero D, Homs M, Gregori J, Riveiro-Barciela M, Ruiz A, Esteban R, Buti M, Rodríguez-Frías F.

Virus Res. 2018 Jan 2;243:52-59. doi: 10.1016/j.virusres.2017.10.003. Epub 2017 Oct 4.

PMID:
28988126

Supplemental Content

Support Center